BNF:

13.5.3

Status:

Red

Decision Date:

May 2017

Comments

RED^1,2,3 : NICE TA 442 - Ixekizumab for treating moderate to severe plaque psoriasis. (Decision date - May 2017)

RED^1,2,3: NICE TA537 - ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs.(Decision date  - September 2018)

RED1,2,3: NICE TA718 - Ixekizumab  for treating active axial spondylitis. (Decision date - August 2021)

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again